Travis Mickle, KemPharm CEO (via KemPharm)

Or­p­hazyme agrees to sell it­self, and its 'pipeline-in-a-prod­uct,' to Kem­Pharm

Two months ago, Or­p­hazyme en­list­ed the help of the Dan­ish courts to help over­see a re­struc­tur­ing in the wake of tri­al fail­ures, C-suite shake­ups and reg­u­la­to­ry re­jec­tions. The move was ex­pect­ed to help the com­pa­ny find a way to ei­ther sell it­self or its as­sets, at­tempt­ing to keep the re­search go­ing on what it once called its “pipeline-in-a-prod­uct.”

On Sun­day, the res­o­lu­tion of the court-run ef­forts came in­to view.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.